308 related articles for article (PubMed ID: 32141702)
41. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
42. A pharmacogenomic analysis using L1000CDS
Choi EA; Choi YS; Lee EJ; Singh SR; Kim SC; Chang S
Cancer Lett; 2019 Nov; 465():82-93. PubMed ID: 31404615
[TBL] [Abstract][Full Text] [Related]
43. Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma.
Ben Q; Sun Y; Liu J; Wang W; Zou D; Yuan Y
Pancreatology; 2020 Jun; 20(4):698-708. PubMed ID: 32354626
[TBL] [Abstract][Full Text] [Related]
44. MEIS1 inhibits clear cell renal cell carcinoma cells proliferation and in vitro invasion or migration.
Zhu J; Cui L; Xu A; Yin X; Li F; Gao J
BMC Cancer; 2017 Mar; 17(1):176. PubMed ID: 28270206
[TBL] [Abstract][Full Text] [Related]
45. Upregulated long noncoding RNA LINC01296 indicates a dismal prognosis for pancreatic ductal adenocarcinoma and promotes cell metastatic properties by affecting EMT.
Yuan Q; Zhang Y; Feng L; Jiang Y
J Cell Biochem; 2019 Jan; 120(1):552-561. PubMed ID: 30203487
[TBL] [Abstract][Full Text] [Related]
46. Human amniotic fluid mesenchymal stem cells attenuate pancreatic cancer cell proliferation and tumor growth in an orthotopic xenograft mouse model.
Chen YC; Lan YW; Huang SM; Yen CC; Chen W; Wu WJ; Staniczek T; Chong KY; Chen CM
Stem Cell Res Ther; 2022 Jun; 13(1):235. PubMed ID: 35659367
[TBL] [Abstract][Full Text] [Related]
47. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Zheng X; Carstens JL; Kim J; Scheible M; Kaye J; Sugimoto H; Wu CC; LeBleu VS; Kalluri R
Nature; 2015 Nov; 527(7579):525-530. PubMed ID: 26560028
[TBL] [Abstract][Full Text] [Related]
48. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
49. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells.
Wu YS; Chung I; Wong WF; Masamune A; Sim MS; Looi CY
Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):296-306. PubMed ID: 27750041
[TBL] [Abstract][Full Text] [Related]
50. Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Int J Oncol; 2011 Mar; 38(3):797-805. PubMed ID: 21225226
[TBL] [Abstract][Full Text] [Related]
51. Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways.
Guo Y; Tong Y; Zhu H; Xiao Y; Guo H; Shang L; Zheng W; Ma S; Liu X; Bai Y
Cell Biol Toxicol; 2021 Jun; 37(3):479-496. PubMed ID: 33070227
[TBL] [Abstract][Full Text] [Related]
52. The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells.
Giannuzzo A; Pedersen SF; Novak I
Mol Cancer; 2015 Nov; 14():203. PubMed ID: 26607222
[TBL] [Abstract][Full Text] [Related]
53. C1GALT1 high expression is associated with poor survival of patients with pancreatic ductal adenocarcinoma and promotes cell invasiveness through integrin α
Kuo TC; Wu MH; Yang SH; Chen ST; Hsu TW; Jhuang JY; Liao YY; Tien YW; Huang MC
Oncogene; 2021 Feb; 40(7):1242-1254. PubMed ID: 33420364
[TBL] [Abstract][Full Text] [Related]
54. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma.
Wang X; Li H; Lu X; Wen C; Huo Z; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
Cell Death Dis; 2018 Sep; 9(10):940. PubMed ID: 30237397
[TBL] [Abstract][Full Text] [Related]
55. Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma.
Li Y; Zheng Z; Xiao L; Chen Y; Liu X; Long D; Chai L; Li Y; Tan C
Anticancer Drugs; 2024 Feb; 35(2):140-154. PubMed ID: 37694833
[TBL] [Abstract][Full Text] [Related]
56. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
[TBL] [Abstract][Full Text] [Related]
57. Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).
Li Z; Lin P; Gao C; Peng C; Liu S; Gao H; Wang B; Wang J; Niu J; Niu W
Tumour Biol; 2016 Apr; 37(4):5117-31. PubMed ID: 26547582
[TBL] [Abstract][Full Text] [Related]
58. IQGAP1 promotes pancreatic cancer progression and epithelial-mesenchymal transition (EMT) through Wnt/β-catenin signaling.
Hu W; Wang Z; Zhang S; Lu X; Wu J; Yu K; Ji A; Lu W; Wang Z; Wu J; Jiang C
Sci Rep; 2019 May; 9(1):7539. PubMed ID: 31101875
[TBL] [Abstract][Full Text] [Related]
59. Norepinephrine enhances cell viability and invasion, and inhibits apoptosis of pancreatic cancer cells in a Notch‑1‑dependent manner.
Qian W; Lv S; Li J; Chen K; Jiang Z; Cheng L; Zhou C; Yan B; Cao J; Ma Q; Duan W
Oncol Rep; 2018 Nov; 40(5):3015-3023. PubMed ID: 30226612
[TBL] [Abstract][Full Text] [Related]
60. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.
Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ
World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
